{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifpt22pgszqm4sokbucve6rynwobgguv2svo6pvbybqetb76xonsq",
    "uri": "at://did:plc:wwyqal4cnqhuwyacdj7rqq3n/app.bsky.feed.post/3mlncjwtsumi2"
  },
  "path": "/t/where-are-the-exceptional-responders/17961#post_13",
  "publishedAt": "2026-05-12T07:09:53.000Z",
  "site": "https://discourse.datamethods.org",
  "tags": [
    "this NYT piece",
    "10.1001/jamaneurol.2025.4946"
  ],
  "textContent": "It’s fascinating to contrast how this NYT piece (rightly, IMO) extols the exceptional responses from a trial of tofersen in _SOD1_ -ALS, whereas the formal study report [1] squirrels these extraordinary findings away in the Results, Discussion and Supplement 1!\n\nThe abstract gives no hint of the exceptional responses:\n\n\nHere is how the Discussion couched the obvious in statistical language:\n\n\nFrom Supplement 1:\n\n\n  1. Miller TM, Cudkowicz ME, Shaw PJ, et al. Long-Term Tofersen in _SOD1_ Amyotrophic Lateral Sclerosis. _JAMA Neurol_. 2026;83(2):115. doi:10.1001/jamaneurol.2025.4946\n\n",
  "title": "Where are the exceptional responders?"
}